Shots:

• The P-III (DESTINY-Breast03) trial evaluating Enhertu (5.4mg/kg) vs T-DM1 in 524 patients with HER2+ unresectable & [or] metastatic breast cancer
• The results showed OS benefits (94.1% vs 86.0%) @12mos. & (77.4% vs 69.9%) @24mos., 36% reduction in risk of death, m-OS (not reached) after a median duration of follow-up of 28.4 vs 26.5mos., 77.4% were alive vs 69.9% @2yr. The results were published in The Lancet
• PFS improvement with m-PFS (28.8 vs 6.8mos.) as assessed by BICR & (40.5 vs 25.7mos.) by the investigator, ORR (78.5% vs 35.0%), CR (21.1% vs 9.5%), PR (57.5% vs 25.5%), SD (18.0% vs 41.8%), PD (1.1% vs 17.9%), m-DoR (36.6 vs 23.8mos.). The safety was consistent with prior trials with no new safety concerns, grade ≥3 TEAEs (47.1%)

Ref: Businesswire | Image: Daiichi Sankyo